期刊文献+

原发性骨质疏松症基层诊疗指南(2019年) 被引量:51

Guideline for primary care of primary osteoporosis(2019)
原文传递
导出
摘要 一、概述(一)定义骨质疏松症(osteoporosis)是一种以骨量低、骨组织微结构损坏导致骨脆性增加、易发生骨折为特征的全身性代谢性骨病。骨质疏松症可发生于任何年龄,但多见于绝经后女性和老年男性。(二)分类骨质疏松症按病因分为原发性和继发性两大类。原发性骨质疏松症包括绝经后骨质疏松症(Ⅰ型)、老年骨质疏松症(Ⅱ型)和特发性骨质疏松症(包括青少年型)。绝经后骨质疏松症一般发生在女性绝经后5~10年内;老年骨质疏松症一般指70岁以后发生的骨质疏松;特发性骨质疏松症主要发生在青少年,病因尚未明。继发性骨质疏松症指由任何影响骨代谢的疾病和/或药物及其他明确病因导致的骨质疏松。
作者 刘静 祝墡珠 贾伟平 江孙芳 刘菊香 无;Liu Jing;Zhu Shanzhu(Chinese Medical Association;Chinese Medical Journals Publishing House;Chinese Society of General Practice;Editorial Board of Chinese Journal of General Practitioners of Chinese Medical Association;Expert Group of Guidelines for Primary Care of Endocrine System Disease;Diagnosis and Treatment Center for Endocrine and Metabolic Disease,Gansu Provincial Hospital,Laruhou 730000,China;Department of General Practice,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处 《中华全科医师杂志》 2020年第4期304-315,共12页 Chinese Journal of General Practitioners
关键词 指南 骨质疏松
  • 相关文献

参考文献6

二级参考文献79

  • 1Questions and answers on the review of calcitonin-containing medicine[EB/OL] .(2012-07-19)[2013-12-19] .http:// www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/calcitonin-31/WC500130149.pdf.
  • 2Cruber HE,Ivey JL,Baylink DJ,et al.Long-term calcitonin therapy in postmenopausal osteoporosis[J] .Metabolism,1984,33:295-303.
  • 3Chesnut III CH,Silvemen S,Andriano K,et al.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis:the prevent recurrence of osteoporotic fracture study.PROOF Study Group[J] .Am J Med,2000,109:267-276.
  • 4Andrews NA.Calcitono therapy:is the story coming to an end?[EB/OL] .(2012-01-23)[2013-12-19] .IBMS Bone KEY,2013,10:260.doi:10.1.38/bonekey.2012.260 www.nature.com/bonekey.
  • 5U.S.Foood and Drug Administration,Center for Drug Evaluation and Research.Guideline for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis.(Draft Guideline undergoing finalization).
  • 6Kanis JA,Buriet N,Cooper C,et al.European guideline for the diagnosis and management of osteoporosis in postmenopausal women[J] .Osteoporos Int,2013,24:23-57.
  • 7National Osteoporosis Foundation.2013 Clinician's Guide to Prevention and Treatment of Osteoporosis[EB/OL].(2012-01-23)[2013-12-19].Washington,DC:National Osteoporosis Foundation;2013.http://www.nof.org/sites/default/files/pdfs/NOF_Clinicians_Guide2013.pdf.
  • 8NAMS continuing medical education activity:management of osteoporosis in postmenopausal women:2010 position statement of the North American Menopause Society[J] .Menopause,2010,17:23-54.
  • 9Watts NB,Bilezikian JP,Camacho PM,et al.American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis[J] .Endocrine Practice.2010,16(Suppl 3):1-37.
  • 10Lopes RF,Coeli CM,Vaisman M,et al.Additional beneficial effects of recombinant growth hormone in alendronate -treated patients with idiopathic osteoporosis. Endocrine Journal . 2009

共引文献182

同被引文献578

引证文献51

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部